by Ket Patel | Aug 29, 2012 | All Articles For Neurology, Movement Disorders
Existing data support the use of physiotherapy in the treatment of Parkinson’s disease in the short term, but larger, randomized controlled trials of longer duration are needed to better define the benefit of the intervention. That’s the overall conclusion from a...
by Ket Patel | Aug 28, 2012 | All Articles For Neurology, Alzheimer's Disease
Measurements of five protein biomarkers in the cerebrospinal fluid helped to differentiate Alzheimer’s disease from Parkinson’s disease with dementia and from dementia with Lewy bodies in a cross-sectional study of individuals at Swedish neurology and memory disorder...
by Ket Patel | Aug 28, 2012 | All Articles For Neurology, Neuro-Oncology
The impact of acetyl-l-carnitine on chemotherapy-induced peripheral neuropathy may depend largely on the clinical context and patient population, a pair of phase III trials suggests. Acetyl-l-carnitine (ALC), a natural substance marketed over the counter as a dietary...
by Ket Patel | Aug 26, 2012 | All Articles For Neurology, Epilepsy
Pediatric stroke survivors had an absolute risk of 39% for developing epilepsy in the 10 years following their stroke in a review of 371 patients in Northern California. Two factors significantly boosted a child’s risk of developing epilepsy following a stroke: A...
by Ket Patel | Aug 25, 2012 | All Articles For Neurology, Alzheimer's Disease
Eli Lilly’s experimental Alzheimer’s drug solanezumab failed to have statistically significant benefits in the primary end points of two phase III trials but showed possible early cognitive benefits in secondary analyses, the company announced Aug. 24. The...
